Found 28 results
Author [ Title(Asc)] Type Year
Filters: Author is Dally, L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
B. S. Peters, Jaoko, W., Vardas, E., Panayotakopoulos, G., Fast, P., Schmidt, C., Gilmour, J., Bogoshi, M., G Manyonyi, O., Dally, L., Klavinskis, L., Farah, B., Tarragona, T., Bart, P. - A., Robinson, A., Pieterse, C., Stevens, W., Thomas, R., Barin, B., and Bwayo, J. [..], Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity, Vaccine, vol. 25, pp. 2120-2127, 2007.
L. Van Damme, Niruthisard, S., Atisook, R., Boer, K., Dally, L., Laga, M., Lange, J. M., Karam, M., and Perriens, J. H., Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection, AIDS, vol. 12, pp. 433-7, 1998.
W. Jaoko, Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., Adams, E., Graham, B., Koup, R., Bailer, R., Smith, C., Dally, L., Farah, B., Anzala, O., Muvunyi, C., Bizimana, J., Tarragona-Fiol, T., Bergin, P., Hayes, P., Ho, M., Loughran, K., and Komaroff, W., Safety and Immunogenicity Study of Multiclade HIV-1 Adeno-Viral Vector Vaccine Alone or as Boost Following a Multiclade HIV-1 DNA Vaccine in Africa, PLoS ONE, vol. 5, p. e12873, 2010.
W. Jaoko, Kayitenkore, K., G Manyonyi, O., Karita, E., Schmidt, C., Fast, P., Komaroff, W., Cooper, A., Boaz, M., Gilmour, J., Dally, L., Ho, M., Smith, C., and Graham, B., Safety and Immunogenicity of VRC Multiclade HIV-1 Adenoviral Vector Vaccine Alone or with VRC Multiclade HIV-1 DNA Plasmid Vaccine in the African Adults, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
J. W, FN, N., O, A., G, O. Manyonyi, J, B., A, N., F, B., K, B., H, O., S, W., L, M., W, W., J, O., M, O., J, I., J, N. - A., C, K., ,, Smith, C., Barin, B., Dally, L., ,, and Kaleebu, P., Safety and Immunogenicity of Recombinant Low-Dosage HIV-1 A Vaccine Candidates Vectored by Plasmid pTHr DNA or Modified Vaccinia Virus Ankara (MVA) in Humans in East Africa, Vaccine, vol. 26, pp. 2788-2795, 2008.
E. Vardas, Pantaleo, G., Bart, P. A., Robinson, A., Pieterse, C., Thomas, R., McIntyre, J., Gray, G., Bogoshi, M., Mayaphi, S., Fast, P., Schmidt, C., Gilmour, J., Tarragona, T., Smith, C., and Dally, L., Safety and Immunogenicity of MVA.HIVA by 3 Different Routes, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
P
A. L. Fontanet, Saba, J., Chandelying, V., Sakondhavat, C., Bhiraleus, P., Rugpao, S., Chongsomchai, C., Kiriwat, O., Tovanabutra, S., Dally, L., Lange, J. M., and Rojanapithayakorn, W., Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial, AIDS, vol. 12, pp. 1851-9, 1998.
A. Guimarães-Walker, Mackie, N., McMichael, A., Weber, J., McCormack, S., Cebere, I., Kay, R., Hanke, T., Dally, L., Gibiansky, L., Legg, K., DeSouza, C., Hayes, P., Gilmour, J., and Fast, P., Priming with a Candidate HIV-1 Clade A DNA Vaccine Followed by Boosting with an HIV-1 Clade A MVA Vaccine in Volunteers at Low risk of HIV Infection, in AIDS Vaccine 2004 International Conference, Lausanne, Switzerland, 2004.
G. Omosa-Manyonyi, Mpendo, J., Ruzagira, E., Kilembe, W., Chomba, E., Roman, F., Bourguignon, P., Koutsoukos, M., Collard, A., Voss, G., Laufer, D., Stevens, G., Hayes, P., Clark, L., Cormier, E., Dally, L., Barin, B., ,, Gilmour, J., Cox, J., Fast, P., and Priddy, F., A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults, PLoS One, vol. 10, p. e0125954, 2015.
B. Peters, Jaoko, W., Anzala, O., Judges, L., G Manyonyi, O., Sharp, A., Gray, K., Fast, P., Schmidt, C., Gilmour, J., Smith, C., Dally, L., Loughran, K., Farah, B., Tarragona, T., Hayes, P., McMichael, A., Hanke, T., and Bwayo, J., Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
E. Vardas, Kaleebu, P., Bekker, L., Hoosen, A., Chomba, E., Johnson, P., Heald, A., Anklesaria, P., Dally, L., Boaz, M., Fast, P., and Schmidt, C., A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant Adeno-Associated Virus HIV Vaccine, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
S. Vasan, Schlesinger, S., Huang, Y., Hurley, A., Lombardo, A., Chen, Z., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Schmidt, C., Song, Y., Seamons, L., Dally, L., Ho, M., Smith, C., Markowitz, M., Cox, J., Gill, D., and Gilmour, J., Phase 1 Safety and Immunogenicity Evaluation of ADVAX a Multigenic, DNA-Based Clade C/B’ HIV-1 Candidate Vaccine, PLoS ONE, vol. 5, p. e8617, 2010.
C
A. Kamali, Karita, E., Kayitenkore, K., Kaleebu, P., Nanvubya, A., Anzala, O., Jaoko, W., Mutua, G., Ruzagira, E., Mulenga, J., Sanders, E., Mwangome, M., Allen, S., Amornkul, P., Price, M., Stevens, G., Dally, L., Excler, J., and , A Cross-Sectional Study in Eastern and Southern Africa to Characterize Laboratory Reference Intervals in Healthy Adults for HIV Prevention Trials, in AIDS Vaccine 2008 Conference, Cape Town, South Africa, 2008.
E. Karita, Ketter, N., Price, M., Kayitenkore, K., Kaleebu, P., Nanvubya, A., Anzala, O., Jaoko, W., Mutua, G., Ruzagira, E., Mulenga, J., Sanders, E., Mwangome, M., Allen, S., Bwanika, A., Bahemuka, U., Awuondo, K., Omosa, G., Farah, B., Amornkul, P., Birungi, J., Yates, S., Stoll-Johnson, L., Gilmour, J., Stevens, G., Shutes, E., Manigart, O., Hughes, P., Dally, L., Scott, J., Stevens, W., Fast, P., and Kamali, S., CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa, PLoS ONE, vol. 4, no. 2, p. e4401, 2009.
E. Karita, Anzala, O., Gazzard, B., Bergin, P., Nyombayire, J., Omosa, G., ,, Dally, L., Barin, B., Inoue, M., Hara, H., Hironaka, T., Shu, T., Hasegawa, M., Matano, T., Sayeed, E., Parks, C., Ackland, J., Fast, P., Gilmour, J., Cox, J., Lombardo, A., and Laufer, D., Clinical Safety and Immunogenicity of Two HIV Vaccines SeV-G(NP) and Ad35-GRIN in HIV-uninfected, Healthy Adult Volunteers, in HIVR4P (HIV Research for Prevention), Cape Town, South Africa, 2014.
A. Vigano, Dally, L., Bricalli, D., Sala, N., Pirillo, M., Saresella, M., Trabattoni, D., Vella, S., Clerici, M., and Principi, N., Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection, J Pediatric, vol. 135, pp. 675-82, 1999.
O. G Manyonyi, Jaoko, W., Wakasiaka, S., Bwayo, J., Achola, N. J., Schmidt, C., Bhatt, K., Ogutu, H., K’owino, D., Dally, L., Malogo, R., and Fast, P., Challenges Experienced By the Clinical Team During The Conduct of HIV Vaccine Clinical Trials in Kenya, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
A. Mariotto, Dally, L., Micheli, A., Canario, F., and Verdecchia, A., Cancer prevalence in Italian regions with local cancer registries, Tumori, vol. 85, pp. 400-7, 1999.